AVXS-101 (AveXis) Updates
AVXS-101 uses harmless, genetically-engineered viruses to increase SMN protein levels. It has recently received “Breakthrough Therapy” status. AveXis, the pharmaceutical company developing AVXS-101, has released results from the completed Phase I trial of the gene therapy drug.
Drug Development Updates: